# Who does Daiichi Sankyo pay? Who are its key suppliers?
Canonical: https://valuechain.wiki/daiichi-sankyo · Facet: suppliers · Updated: 2026-07-12T04:47:15.227617+00:00 · Source: ValueChain.wiki (cited money-flow graph)

**Citable summary**: Daiichi Sankyo's confirmed suppliers/cost counterparties include Alteogen plus 1 undisclosed/aggregate relationship. Per the valuechain.wiki graph: 2 cost edges, backed by 2 dated sources, 2 of them primary filings (as of 2026-07-12).

### 연구개발·임상 (DXd ADC 파이프라인) (high)
- metric: Amount ¥462.1B · 연구개발비(+29.4 YoY) · Daiichi Sankyo FY2025 IR
- note: R&D spending on the next-generation DXd ADC pipeline (five medicines, 20+ indications) and clinical trials is a major cost. FY2025 R&D expenses were JPY 462.1bn, up JPY 29.4bn year on year, driven mainly by increased 5DXd ADC investment.
- [confirms] Daiichi Sankyo IR (EN, filing, published 2026-04-28) https://www.daiichisankyo.com/files/investors/library/materials/2026/FY2025%20Financial%20Results%20and%205Year%20Business%20Plan%20Presentation_E.pdf: "R&D expenses 432.9 → 462.1 (+29.4). Increase in 5DXd ADCs R&D investments."

### 알테오젠 (high)  → /alteogen.md
- metric: Amount $300M · 최대 총 계약금액 + 로열티 · DART annual report
- note: Licenses Alteogen's ALT-B4 exclusively to develop a subcutaneous (SC) form of the ADC cancer drug Enhertu (Nov 2024); up to US$300M plus royalties, with a US$20M upfront paid Dec 2024.
- [confirms] FSS DART (KO, filing, published 2026-03-23) https://opendart.fss.or.kr/api/document.xml?rcept_no=20260323001596: "Exclusively licensed ALT-B4 to Daiichi Sankyo for a subcutaneous Enhertu formulation; US$20m upfront, up to US$300m including milestones plus sales royalties."

Reverse side: https://valuechain.wiki/daiichi-sankyo/customers.md · Ripple: https://valuechain.wiki/daiichi-sankyo/ripple.md

---
Full node: https://valuechain.wiki/daiichi-sankyo.md · JSON: https://valuechain.wiki/daiichi-sankyo.json